COG-ANHL01P1 (CINJ 110423): A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated with LMB/FAB Therapy (110423).

Trial Profile

COG-ANHL01P1 (CINJ 110423): A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated with LMB/FAB Therapy (110423).

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2013

At a glance

  • Drugs Rasburicase (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Hydrocortisone; Methotrexate; Methylprednisolone; Prednisone; Vincristine
  • Indications B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Lymphoid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Jul 2010 Actual end date (October 2009) added as reported by ClinicalTrials.gov.
    • 28 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top